Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Tong M, Leão R, Vimbela GV, Yalcin EB, Kay J, Krotow A, de la Monte SM.

Mol Cell Neurosci. 2017 Jul;82:23-34. doi: 10.1016/j.mcn.2017.04.010. Epub 2017 Apr 21.

PMID:
28438696
2.

Dynamics of diabetes and obesity: Epidemiological perspective.

Boles A, Kandimalla R, Reddy PH.

Biochim Biophys Acta. 2017 May;1863(5):1026-1036. doi: 10.1016/j.bbadis.2017.01.016. Epub 2017 Jan 24. Review.

PMID:
28130199
3.

Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Kandimalla R, Thirumala V, Reddy PH.

Biochim Biophys Acta. 2017 May;1863(5):1078-1089. doi: 10.1016/j.bbadis.2016.08.018. Epub 2016 Aug 25. Review.

PMID:
27567931
4.

Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

Tong M, Dominguez C, Didsbury J, de la Monte SM.

J Alzheimers Dis Parkinsonism. 2016 Jun;6(3). pii: 238. Epub 2016 Jun 3.

5.

Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal.

Sandhir R, Gupta S.

World J Diabetes. 2015 Sep 25;6(12):1223-42. doi: 10.4239/wjd.v6.i12.1223. Review.

6.

Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain.

Tong M, Yu R, Deochand C, de la Monte SM.

Alcohol Alcohol. 2015 Nov;50(6):670-9. doi: 10.1093/alcalc/agv101. Epub 2015 Sep 15.

7.
8.

Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.

Kim B, Feldman EL.

Exp Mol Med. 2015 Mar 13;47:e149. doi: 10.1038/emm.2015.3. Review.

9.

Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism.

Grieb P.

Mol Neurobiol. 2016 Apr;53(3):1741-1752. doi: 10.1007/s12035-015-9132-3. Epub 2015 Mar 7. Review.

10.

Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.

Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE.

J Neuroinflammation. 2015 Jan 16;12:7. doi: 10.1186/s12974-014-0229-9.

11.

Effects of treadmill exercise on brain insulin signaling and β-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats.

Kang EB, Cho JY.

J Exerc Nutrition Biochem. 2014 Mar;18(1):89-96. doi: 10.5717/jenb.2014.18.1.89. Epub 2014 Feb 13.

12.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials.

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17. Review.

13.

Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.

Kim JW, Seung H, Kwon KJ, Ko MJ, Lee EJ, Oh HA, Choi CS, Kim KC, Gonzales EL, You JS, Choi DH, Lee J, Han SH, Yang SM, Cheong JH, Shin CY, Bahn GH.

PLoS One. 2014 Aug 18;9(8):e104927. doi: 10.1371/journal.pone.0104927. eCollection 2014.

14.

Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

de la Monte SM.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1954-60. doi: 10.1016/j.euroneuro.2014.06.008. Epub 2014 Jun 28. Review.

15.

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.

Yarchoan M, Arnold SE.

Diabetes. 2014 Jul;63(7):2253-61. doi: 10.2337/db14-0287. Epub 2014 Jun 15. Review.

16.

Temporal dystrophic remodeling within the intrinsic cardiac nervous system of the streptozotocin-induced diabetic rat model.

Menard CE, Durston M, Zherebitskaya E, Smith DR, Freed D, Glazner GW, Tian G, Fernyhough P, Arora RC.

Acta Neuropathol Commun. 2014 Jun 4;2:60. doi: 10.1186/2051-5960-2-60.

17.

Nuclear receptors in neurodegenerative diseases.

Skerrett R, Malm T, Landreth G.

Neurobiol Dis. 2014 Dec;72 Pt A:104-16. doi: 10.1016/j.nbd.2014.05.019. Epub 2014 May 27. Review.

18.

Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits.

Kummer MP, Schwarzenberger R, Sayah-Jeanne S, Dubernet M, Walczak R, Hum DW, Schwartz S, Axt D, Heneka MT.

Mol Neurobiol. 2015 Apr;51(2):661-71. doi: 10.1007/s12035-014-8743-4. Epub 2014 May 17.

19.

Amyloid beta: multiple mechanisms of toxicity and only some protective effects?

Carrillo-Mora P, Luna R, Colín-Barenque L.

Oxid Med Cell Longev. 2014;2014:795375. doi: 10.1155/2014/795375. Epub 2014 Feb 5. Review.

20.

Relationships between diabetes and cognitive impairment.

de la Monte SM.

Endocrinol Metab Clin North Am. 2014 Mar;43(1):245-67. doi: 10.1016/j.ecl.2013.09.006. Epub 2013 Dec 12. Review.

Supplemental Content

Support Center